The gut microbiota, a complex community of microorganisms residing in our intestines, has been increasingly implicated in various aspects of human health, including cardiovascular conditions. A new review published in Archives of cardiovascular diseases delves into the potential of gut microbiota-targeted interventions—specifically probiotics, prebiotics, and synbiotics—in the context of coronary artery disease (CAD).

Understanding the Role of Gut Microbiota

Coronary artery disease is a condition characterized by the narrowing or blockage of the coronary arteries, often leading to heart attacks or other serious cardiovascular events. Recent research has suggested that gut microbiota dysbiosis, an imbalance in the microbial community, may contribute to the development of atherosclerosis and systemic inflammation, which are key factors in CAD. This review explores whether interventions targeting the gut microbiota can influence these processes.

Review Findings: Current Evidence and Gaps

The review analyzed data from six human studies that met specific criteria, including three randomized controlled trials, one non-randomized controlled intervention study, one before-after study, and one cross-sectional study. These studies investigated the effects of probiotic, prebiotic, or synbiotic supplementation in individuals with stable CAD. Notably, none of the studies included patients with acute coronary syndromes (ACS), a more severe form of CAD.

Findings from the randomized trials indicated improvements in certain inflammatory biomarkers, angina symptoms, and endothelial function. Two studies that focused on synbiotic interventions reported reductions in circulating lipopolysaccharide and inflammatory cytokines, along with improved nitric oxide bioavailability, which is important for vascular health. However, the review highlights a significant gap: no study assessed major adverse cardiovascular events, recurrent ACS, or mortality as pre-specified endpoints.

Implications and Future Directions

The review underscores the potential of microbiota-targeted interventions in stable CAD, suggesting that synbiotics, which combine prebiotics and probiotics, may offer complementary benefits by modulating the gut microbiota. Despite promising mechanistic and biomarker evidence, the role of these interventions after ACS remains largely unexplored. This gap is significant because ACS patients could potentially benefit from novel therapeutic strategies aimed at reducing inflammation and improving cardiovascular outcomes.

To address this gap, the authors of the review are conducting a pilot trial, SYMBIO-ACS, to investigate the effects of synbiotic supplementation in patients after ACS. This trial aims to provide initial mechanistic and clinical evidence that could inform future research and potential therapeutic applications.

Limitations and Considerations

While the review provides valuable insights, it is important to acknowledge its limitations. The small number of studies included, and the absence of research specifically targeting ACS, highlight the preliminary nature of the evidence. Furthermore, the variability in study designs and interventions makes it challenging to draw definitive conclusions. Future research should focus on well-designed, large-scale trials that assess clinically relevant endpoints to better understand the potential of gut microbiota-targeted interventions in CAD.

For more on the gut microbiome's role in health, you might explore our article on what is the microbiome.

Frequently asked

What are synbiotics?

Synbiotics are a combination of probiotics and prebiotics. Probiotics are live microorganisms that can provide health benefits, while prebiotics are non-digestible food components that promote the growth of beneficial bacteria in the gut.

Why is gut microbiota important in coronary artery disease?

Gut microbiota is thought to influence coronary artery disease through mechanisms like inflammation and atherogenesis, the process of plaque formation in the arteries. Dysbiosis, or an imbalance in gut bacteria, may contribute to these processes.

What did the review find about probiotics and prebiotics in CAD?

The review found that some studies reported improvements in inflammatory biomarkers and endothelial function with probiotic and synbiotic interventions in stable CAD. However, there is a lack of research specifically in acute coronary syndromes.

Editorial content for general information only — not medical advice, diagnosis or treatment. Talk to a qualified clinician about your own health.